Saturday 17 October 2026
Export YDES’s income statement to Excel — free account
YD Bio Limited
YDES Healthcare Biotechnology
Insiders bought in the last twelve months.
5.92
0.82
−12.17%
Follow YDES
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 5.30 | 1.70 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 25.00 | 13.11 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | — | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | — | — | — | — | |||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| Net income | — | — | — | — | — | — | — | — | — | — | |||||
| Depreciation | — | — | — | — | — | — | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Earnings | — | — | — | — | — | — | — | — | — | — | |||||
| Cash flow | — | — | — | — | — | — | — | — | — | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | |||||
| Book value | — | — | — | — | — | — | — | — | — | — | |||||
| Shares, m | — | — | — | — | — | — | — | — | — | — | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | — | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | — | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | — | — | — | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | — | — | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | — | — | ||||
| ROIC | — | — | — | — | — | — | — | — | — | — | |||||
| ROE | — | — | — | — | — | — | — | — | — | — | |||||
Negative figures in brackets.
Charts ten years each
YD Bio Limited vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics Inc. | $481.9M | — (loss-making) | — | — | n/m | −201.41% (below 0%: shrinking) | — | 0.00% | Compare |
| ENTX Entera Bio Ltd. | $481.5M | — (loss-making) | — (loss-making) | +200.00% (above 0%: growing) | n/m | −108.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NGNE Neurogene Inc. | $479.3M | — (loss-making) | — (loss-making) | — | n/m | −22.97% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| YDES YD Bio Limited | $477.5M | — | — | — | — | — | — | — | |
| RGNX REGENXBIO Inc. | $472.7M | — (loss-making) | — (loss-making) | +405.73% (above 0%: growing) | n/m | −26.67% (below 0%: shrinking) | 99.04% | 27.09% | Compare |
| ARVN Arvinas, Inc. | $468.2M | 53.6× | — (loss-making) | +1,014.73% (above 0%: growing) | n/m | +49.79% (above 0%: growing) | 96.40% | 65.72% | Compare |
| CBIO Crescent Biopharma, Inc. | $463.6M | — (loss-making) | — (loss-making) | +1,038,900.00% (above 0%: growing) | n/m | −7.04% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ALLO Allogene Therapeutics, Inc. | $463.0M | — (loss-making) | — (loss-making) | +20,990.91% (above 0%: growing) | n/m | +17.73% (above 0%: growing) | 100.00% | (1,011.21%) | Compare |
| ALT Altimmune, Inc. | $459.1M | — (loss-making) | — (loss-making) | +520.00% (above 0%: growing) | n/m | −25.27% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $470.4M | — | — | +767.37% | — | −24.12% | 100.00% | 0.00% |